FDA Grants Accelerated Approval to Replimune Melanoma Therapy
By Elaine Chen · STAT News · 2026-08-06

The Food and Drug Administration has authorized Replimune’s oncolytic immunotherapy for patients with advanced melanoma following a series of regulatory setbacks. According to reporting from STAT News, the treatment will be sold under the brand name Tudriqev after an advisory com
The Food and Drug Administration has authorized Replimune’s oncolytic immunotherapy for patients with advanced melanoma following a series of regulatory setbacks. According to reporting from STAT News, the treatment will be sold under the brand name Tudriqev after an advisory com